Merck (MRK) Capital Expenditures (2009 - 2026)

Merck (MRK) has reported Capital Expenditures for 18 consecutive years, with $893.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Capital Expenditures rose 16.88% year-over-year to $893.0 million in Q2 2026; TTM through Jun 2026 was $3.9 billion, a 2.41% increase from a year earlier, with the FY2025 full-year figure at $4.1 billion, up 21.95% from the prior year.
• Capital Expenditures was $893.0 million for Q2 2026 at Merck, down from $991.0 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $1.3 billion in Q1 2025 and troughed at $764.0 million in Q2 2025.
• A 5-year average of $978.8 million and a median of $985.5 million in 2022 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures soared 54.24% in 2025 and decreased 25.38% in 2026, its largest moves.
• Over 5 years, Capital Expenditures stood at $1.1 billion in 2022, then retreated by 13.93% to $989.0 million in 2023, then fell by 5.26% to $937.0 million in 2024, then rose by 10.25% to $1.0 billion in 2025, then declined by 13.55% to $893.0 million in 2026.
• The last three Capital Expenditures figures came in at $893.0 million (Q2 2026), $991.0 million (Q1 2026), and $1.0 billion (Q4 2025), per Business Quant data.